BioSpace News Archive

Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer will participate in two upcoming investor conferences.

IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, announced that its partner Ipsen has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan.

Amcor, a global leader in developing and producing responsible packaging solutions, has announced the first batch of recipients for its ground-breaking Amcor Lift-Off seed funding initiative.

Vizient, Inc. released its latest Medical Device Tech Watch, identifying trends in artificial intelligence, examining treatment options for pulmonary embolism and highlighting strategies to boost clinical workforce retention.

Emergent BioSolutions Inc. announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection.

Rarecells, Inc. announced the appointment of Dr. Neil Gunn, a recognized leader and expert in the diagnostic space, as an independent Board Director.

Evoke Pharma, Inc. (NASDAQ: EVOK), today announced that the Company’s President and CEO, David A. Gonyer, R.Ph., and Chief Business Officer, Matt D’Onofrio, MBA, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place from September 12-14, 2022, at the Lotte New York Palace Hotel in NYC.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company’s chief financial officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference at 2:00 p.m. ET on Tuesday, September 13, 2022, in New York, NY.

Limbix is excited to announce a partnership with Children’s Hospital Los Angeles for a research study to evaluate SparkRx, an adjunct treatment for adolescents with symptoms of depression, in specialty medical care settings.

9 Meters Biopharma, Inc. announced that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022, in New York City.